How to Buy Lexeo Therapeutics Stock
Lexeo Therapeutics Inc
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases.
Lexeo Therapeutics stock last closed at $5.18, up 0% from the previous day, and has decreased 47.52% in one year. It has overperformed other stocks in the Biotechnology industry by 0.01 percentage points. Lexeo Therapeutics stock is currently +257.24% from its 52-week low of $1.45, and -55.8% from its 52-week high of $11.72.
As of Sep 12, 2025, there are 54M shares of LXEO outstanding. The market capitalization of LXEO is $279.73M. In the past 24 hours, 1.22M LXEO shares were traded.
How to Buy Lexeo Therapeutics Stock
Wondering how to invest in Lexeo Therapeutics stock? Here's how.
- Decide where to buy Lexeo Therapeutics stock: You need to decide on an online brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you decide where to buy Lexeo Therapeutics stock.
- Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit money your brokerage account: Select your method of payment and add your info.
- Analyze Lexeo Therapeutics stock: The Lexeo Therapeutics ticker symbol is LXEO. Is Lexeo Therapeutics stock a good investment? Should you buy shares of LXEO? How do LXEO's underlying business fundamentals look? Do top analysts think Lexeo Therapeutics is a good buy? Why has LXEO's stock price moved recently? (Hint: Our stock research tools can help you understand if LXEO is a good stock to buy).
- Make your LXEO buy order: Decide if you will purchase LXEO shares at the current market price or use a limit order to purchase LXEO shares at a particular price.
- Keep an eye on your LXEO investment: Create a watchlist to track your investment in Lexeo Therapeutics shares.
Step 1: Decide where to buy Lexeo Therapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy LXEO stock.
Our favorite brokerage: eToro
Based on our research, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to world financial markets: From Tech to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've selected the best brokerage, the next step is to fill out some personal info so you are able to buy LXEO stock today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to create your new brokerage account.
- Send your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you've finished signing up on one of the most highly reviewed stock trading apps, you need to deposit funds:
Check out the tutorial below if you need help transferring funds into your new brokerage account.
Step 4: Analyze Lexeo Therapeutics stock
After you have identified the best place to buy Lexeo Therapeutics stock, it's crucial to research their stock before you buy, so you actually wrap your head around the risk as well as the opportunity.
Lexeo Therapeutics quick stats
Fundamentals of Lexeo Therapeutics
WallStreetZen was built to help average investors do more accurate fundamental analysis in less time.
You can view all of the due diligence checks on LXEO's stock page.
Is LXEO stock overvalued?
Investors use many financial metrics, analyses, models, and charts to gauge LXEO's true value.
Using relative valuations methods:
- LXEO could be undervalued based on its P/B ratio of 2.02x, relative to Biotechnology industry P/B ratio of 4.65x
You can do additional valuation analysis on LXEO's stock here.
LXEO Financial Summary
Positive Health Checks:
- LXEO has a low debt to equity ratio of 0.27.
- LXEO has $136.14M in cash and short term investments. This is sufficient to cover its annual cash burn of $95.26M.
- There are more short-term assets than long-term liabilities on the LXEO balance sheet.
- There are more short-term assets than short-term liabilities on the LXEO balance sheet.
- LXEO has cash burn of 95258000. It has sufficient cash and short-term investments to cover this for at least one year.
Is it a good time to buy LXEO stock, according to Wall Street analysts?
Out of 7 Wall Street analysts who give recommendations on LXEO, the consensus analyst rating on LXEO is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Most Recent LXEO Analyst Recommendations
Luca Issi, a top 26% analyst from RBC Capital maintains LXEO with a buy rating and lowers their LXEO price target from $24.00 to $20.00, on Mar 25, 2025.
Mani Foroohar, a bottom 1% analyst from Leerink Partners maintains LXEO with a buy rating and lowers their LXEO price target from $19.00 to $18.00, on Mar 24, 2025.
You can dig deeper into what analysts are saying on the Lexeo Therapeutics stock forecast page.
LXEO Momentum
LXEO Earnings
Last year, LXEO revenue was $0.00. During the past 2 year, LXEO's revenue has increased by -100% per year. This was slower than the Biotechnology industry average of 66.52%.
You can research LXEO's earnings and revenue performance here.
Latest Insiders Trades at LXEO
In the last 12 months, executives and large shareholders at LXEO have bought more shares than they have sold.
Eric Adler, Chief Medical Officer of LXEO, was the latest LXEO insider to sell. They sold $2,838.14 worth of LXEO shares on Aug 18, 2025.
Get more info about who owns LXEO stock here.
Can I get consistent income from LXEO stock?
No, Lexeo Therapeutics doesn't provide an income stream by paying out dividends.
What do other investors have to say about LXEO?
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Make your LXEO buy order
There are two primary order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually fine for most investors. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a particular dollar amount limit, place a limit order.
Click the Open Trade button and eToro will execute the order.
If you need more assistance buying stocks on eToro, watch the how to video below:
Step 6: Keep an eye on your LXEO investment
Now that you own some shares in LXEO, you'll want to keep up with your new investment.
Start a watchlist to track your LXEO stock.
LXEO Feed
How to Buy Stock in Lexeo Therapeutics
To reiterate, here are the 6 steps for buying Lexeo Therapeutics stock:
- Decide where to buy Lexeo Therapeutics stock
- Sign up for a brokerage account
- Deposit money your brokerage account
- Analyze Lexeo Therapeutics stock
- Make your LXEO buy order
- Keep an eye on your LXEO investment
If you are looking for a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in Lexeo Therapeutics, create a watchlist on WallStreetZen today.
Trending Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.